Quick Answer
Senti Biosciences Holdings, Inc. reported Revenue (ASC 606) of $22.0 thousand for fiscal year 2025.
Senti Biosciences Holdings, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $22.0K | — |
| 2024 | $0.00 | -100.0% |
| 2023 | $1.98M | -39.8% |
| 2022 | $3.29M | +43.4% |
| 2021 | $2.29M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $0.00 | -100.0% | — |
| June 30, 2024 | $0.00 | -100.0% | — |
| March 31, 2024 | $0.00 | -100.0% | -100.0% |
| September 30, 2023 | $255.0K | -83.2% | -62.9% |
| June 30, 2023 | $687.0K | -38.0% | -33.7% |
| March 31, 2023 | $1.04M | +21.3% | -31.7% |
| September 30, 2022 | $1.52M | +63.7% | +36.8% |
| June 30, 2022 | $1.11M | +42.4% | +29.7% |
- Over the 2021–2025 period, Senti Biosciences Holdings, Inc.’s revenue (asc 606) has declined by 99.0% (from $2.29 million to $22.0 thousand).
- The most recent figure is from Senti Biosciences Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: